Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Euronext Growth Dublin Restoration Notice

27 Aug 2019 13:00

RNS Number : 2902K
Euronext Dublin
27 August 2019
 

CORPORATE EVENT NOTICE:

Restoration Notice

Amryt Pharma Plc

LOCATION:

Dublin

DATE:

27th August 2019

MARKET:

Euronext Growth

 

 

Trading of the under-mentioned securities of Amryt Pharma Plc has been restored, as detailed below.

 

Date and time of the communication

2019-08-27T13:00:00Z

Action type

Restoration of trading

Reasons for the action

Publication of Admission Document in respect of the enlarged entity, in accordance with Euronext Growth Dublin rule 5.19

Effective from

2019-08-27T13:00:00Z

Effective to

Ongoing

True

Trading venue(s)

XESM

Issuer name

Amryt Pharma Plc

Issuer Legal Entity Identifier (LEI)

213800BOS8WAJO2BEQ38

Instrument identifier (ISIN)

GB00BKB1MS30

Instrument full name

Ordinary Shares

Sufficiently related derivatives

Other related instruments

Comments

 

This announcement has been issued through the Companies Announcement Service of Euronext Dublin.

 

The present notice and the contents thereof are only provided for information purposes in order to facilitate the fair, orderly and efficient functioning of the market and is not a recommendation to engage in investment activities. The contents of this notice are provided "as is" based on information provided to the market operator without representation or warranty of any kind. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this notice shall form the basis of any contract. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext's subsidiaries shall depend solely on the applicable rules of the market operator.

 

The Euronext Markets comprise the markets operated by Euronext Amsterdam, Euronext Brussels, Euronext Dublin, Euronext Lisbon, Euronext Paris and Euronext UK Markets, referred to respectively as the Amsterdam, Brussels, Dublin, Lisbon, Paris and London markets, as relevant.

 

Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at https://www.euronext.com/terms-use.

 

© 2019 Euronext N.V. - All rights reserved

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ISEBBGDIXSDBGCR
Date   Source Headline
24th Apr 20177:00 amRNSFirst Patient Enrolled
10th Apr 20175:21 pmRNSDirector/PDMR Shareholding
6th Apr 20174:13 pmRNSPosting of Annual Report 2016 and Notice of AGM
30th Mar 20177:00 amRNSFinal Results
28th Mar 20177:00 amRNSPhase 3 Clinical Trial for AP101 commenced
27th Mar 20177:00 amRNSSenior Management Appointment
8th Mar 20177:00 amRNSNotice of Results
6th Mar 20177:00 amRNSAP101 trial discussions completed with FDA & EMA
9th Feb 20177:00 amRNSDirectorate Change
7th Feb 20177:00 amRNSGrant of patent in Japan for AP101 (Episalvan)
6th Feb 20177:00 amRNSPre-clinical study results
5th Dec 20167:00 amRNSTransformational Licence Agreement
2nd Dec 20167:00 amRNSEUR20m Facility with European Investment Bank
7th Nov 20167:00 amRNSOrphan drug designation for Acromegaly Compound
19th Sep 20167:00 amRNSAppointment of Chief Medical Officer
13th Sep 20167:00 amRNSHalf-year Report
13th Sep 20167:00 amRNSGrant of US patent for lead drug, Episalvan
7th Jul 201612:54 pmRNSResult of AGM
27th Jun 20167:00 amRNSMarkus Ziener appointed as Non-Executive Director
9th Jun 20167:00 amRNSFinancial Results
2nd Jun 20164:34 pmRNSNotice of Results
21st Apr 20164:35 pmRNSHolding(s) in Company
19th Apr 20167:00 amRNSAdmission to trading on AIM and ESM
18th Apr 20162:30 pmRNSESM Schedule 1 Update
18th Apr 20162:30 pmRNSSchedule One update - Fastnet Equity plc
18th Apr 201612:41 pmRNSResult of General Meeting and Change of Name
31st Mar 20167:35 amRNSESM Schedule 1
31st Mar 20167:30 amRNSSchedule One - Fastnet Equity plc
31st Mar 20167:30 amRNSRestoration - Fastnet Equity plc
31st Mar 20167:00 amRNSProposed Acquisition of Amryt Pharmaceuticals
22nd Feb 20167:30 amRNSPotential Acquisition and Statement re Suspension
22nd Feb 20167:30 amRNSSuspension - Fastnet Equity plc
21st Dec 20157:01 amRNSAppointment of Non-executive Director
21st Dec 20157:00 amRNSInterim Results
18th Dec 20157:00 amRNSDemerger of Oil and Gas Assets
30th Sep 20153:12 pmRNSResult of Annual General Meeting
4th Sep 20157:00 amRNSFinal Results
28th Aug 20153:31 pmRNSResult of General Meeting
11th Aug 20153:35 pmRNSProposed adoption of Investing Policy/Notice of GM
3rd Jul 20153:22 pmRNSDirector/PDMR Shareholding
26th Jun 20152:45 pmRNSDirector/PDMR Shareholding
2nd Jun 20152:27 pmRNSHolding(s) in Company
1st Jun 20157:00 amRNSCorporate Update
26th Mar 20157:00 amRNSCeltic Sea Portfolio
27th Jan 201512:56 pmRNSDirectorate Change
9th Jan 201512:49 pmRNSHolding(s) in Company
2nd Jan 20157:00 amRNSExpiry of Tendrara Option Agreement
19th Dec 20147:00 amRNSInterim Results
10th Dec 20147:00 amRNSBoard changes & operational update
1st Dec 20143:00 pmRNSResponse to press speculation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.